One pioneering trial in this area, PALACE-1, a phase Ib trial, enrolled 22 Chinese patients with resectable esophageal squamous cell carcinoma, regardless of PD-L1 status, who received preoperative Pembrolizumab alongside concurrent chemoradiotherapy. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.